strain-specific serologic testing. A spotted fever group rickettsia was isolated in 1950 from a brown dog tick, Rhipicephalus sanguineus, collected in India (2) and assumed to be the agent causing ITT. It was designated as Rickettsia conorii, the agent of Mediterranean spotted fever, which occurs all around the Mediterranean and is transmitted by the same tick species. However, the disease as it appears in India differs from the common description of Mediterranean spotted fever. The rash is frequently purpuric, and an inoculation eschar at the bite site is rarely found, as in this case. The disease as known in India is mild to moderately severe, although our case may be considered severe (1, 3, 4) .
Strain differences within the species R. conorii may account for differences in clinical presentation. Although different isolates of R. conorii can be distinguished antigenically (5-7), molecular taxonomic methods demonstrated recently that these rickettsiae are closely related and cluster together (8-10). Thus, the species is considered by many as R. conorii, including four serovars: R. conorii with three type strains, Seven being the one most commonly identified in our laboratory in isolates from France, Portugal, North Africa (D. Raoult, unpub. data), Kenya, and Morocco (apparently a unique isolate); R. conorii Indian tick typhus; R. conorii Astrakhan, and R. conorii Israel.
Immunofluorescence is the reference diagnostic method for associated rickettsioses, but cross-reactivity among related isolates confounds interpretation of serologic tests. Cross-absorption tests, especially in conjunction with Western blot immunoassays, can be used to determine the rickettsia species involved, as reported in this case. The higher sensitivity of Western blots compared with immunofluorescence has been demonstrated previously in our laboratory; it is frequently positive in acute-phase sera when antibodies cannot be detected by immunofluorescence (11). In this case, we used R. conorii Seven as the type strain of R. conorii because it is most closely related to R. conorii ITT phylogenetically (10). Although these techniques are time-consuming and available only in specialized reference laboratories, they provide data of importance that allow a better understanding of the epidemiology of rickettsioses. 
Multidrug-Resistant Pseudomonas aeruginosa
Producing PER-1 Extended-Spectrum Serine-ß-Lactamase and VIM-2 Metallo-ß-Lactamase
To the Editor: In Pseudomonas aeruginosa, secondary betalactamases with extended substrate specificity can be responsible for acquired resistance to the most powerful antipseudomonal beta-lactams, such as expanded-spectrum cephalosporins and carbapenems (1) . A number of these enzymes have been described, including extended-spectrum serine-beta-lactamases (ESBLs) of groups 2be and 2d (e.g., PER-1 and various OXA-type enzymes) (2,3) and metallobeta-lactamases of group 3 (e.g., IMP-1 and the recently described VIM-1 and VIM-2 enzymes) (2,4,5). The secondary ESBLs can degrade penicillins, expanded-spectrum cephalosporins, and monobactams (but not carbapenems) and are often susceptible to serine-beta-lactamase inhibitors (1-3). The secondary metallo-beta-lactamases, on the other hand, are notable for their carbapenemase activity and can degrade virtually all beta-lactams except monobactams, while being resistant to the currently available inhibitors (1,2,5,6). On March 2000, a multidrug-resistant P. aeruginosa (isolate VA-182/00) was isolated in pure culture from a bronchial washing of a 58-year-old patient with multiple myeloma. The patient had been admitted 15 days earlier to the Varese University Hospital with a diagnosis of pneumonia and had been treated with ciprofloxacin (0.5 g twice a day) plus piperacillin (2 g three times a day) for 12 days, and then with imipenem/cilastatin (0.5 g three times a day). No cultures of respiratory tract specimens were done earlier in hospitalization. Multiple myeloma had been diagnosed in 1997, and the patient had been treated with multiple cycles of antiproliferative chemotherapy and had received autologous peripheral blood stem cell transplantation. According to clinical records, P. aeruginosa had not been isolated previously during this patient's protracted illness. In vitro susceptibility testing showed that the P. aeruginosa isolate was resistant to mezlocillin, ceftazidime, cefepime, aztreonam, imipenem, meropenem, gentamicin, tobramycin, netilmicyn (MICs, >128 µg/mL), amikacin (MIC, 64 µg/mL), ciprofloxacin and levofloxacin (MICs, >32 µg/mL). Only piperacillin and piperacillin/tazobactam had MIC values slightly lower than the breakpoints for resistance (64 µg/mL and 48/4 µg/ mL, respectively), although-considering the normal MICs of piperacillin for susceptible P. aeruginosa (2-8 µg/mL)-it was evident that the isolate also had considerable biological resistance to these drugs. A double disk-diffusion test, carried out with standard disks placed 20 mm apart (center-tocenter), showed synergy between clavulanate and aztreonam. The treatment was changed to piperacillin/tazobactam (4 g four times a day), and a slow recovery ensued over a 30-day period. The patient died 3 months later following a relapse of the underlying malignancy.
The unusually high carbapenem MICs exhibited by VA-182/00 suggested production of a secondary metallo-beta-lactamase, while the synergy between clavulanate and aztreonam suggested production of a secondary serine ESBL. A crude extract of that isolate, assayed spectrophotometrically (7), exhibited imipenem-hydrolyzing activity (94 nmol/min/ mg protein, inhibited by EDTA) as well as aztreonam-hydrolyzing activity (11 nmol/min/mg protein, resistant to EDTA). Analytic isoelectric focusing (IEF) of the extract, followed by development with the nitrocefin chromogenic substrate (7), showed three bands of beta-lactamase activity of pIs 5.4, 5.6, and 6.3, suggesting the presence of at least three different secondary enzymes. A colony-blot hybridization with probes for the bla IMP , bla VIM , and bla PER resistance genes (all of which have been previously detected in P. aeruginosa clinical isolates from the same hospital [8,9; Luzzaro F, unpub. data]) yielded positive results with both the bla VIM and the bla PER probes. Amplification of the resistance genes by polymerase chain reaction (PCR) with primers VIM/DIA-f (5'-CAgATTgCCgATggTgTTTgg) and VIM/DIA-r (5'-AggTgggCCATTCAgCCAgA) for bla VIM genes (4,5) and BLAPER-f (5'-gggACA(g/A)TC(g/C)(g/T)ATgAATgTCA) and BLAPER-r (5'-ggg(C/T)(g/C)gCTTAgATAgTgCTgAT) for bla PER genes (9), yielded amplicons of the expected sizes (522 and 966 bp, respectively). Direct amplicon sequencing identified the two beta-lactamase determinants as bla VIM-2 (5) and bla PER-1 (10), respectively, a finding consistent with the pIs 5.6 and 5.4 beta-lactamase bands detected in IEF (3, 5) . Conjugative transfer of the resistance determinants to Escherichia coli proved unsuccessful. In a Southern blot analysis of total undigested DNA from VA-182/00, both the bla VIM and bla-PER probes apparently hybridized to the chromosomal DNA band; no plasmid bands recognized by either probe were detected. A PCR experiment with primers OXA10-f (5'-ggAACAAAgAgTTCTCTgCC) and OXA105-r (5'-TTAgCCACCAATgATgCC(C/T)TC), suitable for amplification of bla OXA genes of the OXA-10 group, did not yield an amplicon of the expected size (719 bp), suggesting that the pI 6.3 beta-lactamase band detected by IEF did not correspond to an enzyme of this group. This is the first observation of a P. aeruginosa clinical isolate simultaneously producing a secondary PER-1 ESBL and a secondary metallo-beta-lactamase. The finding, observed in a hospital where both the resistance genes
